Eliquis 5 Mg

Eliquis 5 Mg

Description:

Eliquis 5 mg film-coated tablets contain apixaban, an oral prescription anticoagulant (blood thinner) used to prevent and treat serious blood clots. Apixaban is a direct factor Xa inhibitor that helps reduce the formation of harmful clots in the veins and arteries, thereby lowering the risk of stroke, systemic embolism, deep vein thrombosis (dvt), and pulmonary embolism (pe). Eliquis 5 mg is intended for adult patients under the supervision of a healthcare professional and is commonly used in long-term management of nonvalvular atrial fibrillation and venous thromboembolic events.

Indications:

• Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation who have one or more risk factors (such as prior stroke or transient ischemic attack, age ≥75 years, hypertension, diabetes, symptomatic heart failure, etc.).
• Treatment of deep vein thrombosis (dvt).
• Treatment of pulmonary embolism (pe).
• Prevention of recurrent dvt and pe following initial treatment.
• Prophylaxis of dvt that may lead to pe in adult patients who have undergone elective hip or knee replacement surgery.
• Helps reduce complications related to venous thromboembolic events such as leg pain, swelling, chest pain, and shortness of breath associated with clots (when used as directed by a physician).

Active Ingredients / Key Components:

• Apixaban – 5 mg per film-coated tablet.
• Inactive ingredients/excipients: Full excipient list (such as tablet core and coating components, colorants, stabilizers) is not available in the provided information. Refer to the official package leaflet for complete details.

Dosage & Administration / How to Use:

• Eliquis 5 mg is for oral use only and should be swallowed with water. It can be taken with or without food.
• Typical dose for nonvalvular atrial fibrillation in adults: 5 mg twice daily. A reduced dose may be required in certain patients (e.g., elderly, low body weight, or impaired kidney function) as determined by the physician. Exact dosing must follow your doctor’s prescription.
• For treatment of dvt and pe: standard regimens generally start with a higher dose for a short period followed by 5 mg twice daily; your doctor will specify the exact schedule and duration.
• For prevention of recurrent dvt and pe: your doctor may continue Eliquis at 5 mg twice daily or adjust to a lower maintenance dose depending on your risk profile and treatment response.
• For prophylaxis after hip or knee replacement surgery: dosing and duration (usually several days to weeks) are determined by the surgeon or treating physician.
• Take doses at the same times each day to maintain consistent blood levels.
• If you miss a dose, take it as soon as you remember on the same day and then continue with your regular schedule. Do not take a double dose to make up for a missed one unless specifically instructed by your doctor.
• Do not stop taking Eliquis 5 mg without medical advice, as sudden discontinuation may increase the risk of stroke or blood clots.

Clinical Benefits:

• Reduces the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation by inhibiting factor Xa and limiting clot formation.
• Effectively treats deep vein thrombosis (dvt) and pulmonary embolism (pe), helping to resolve existing clots and prevent progression.
• Helps prevent recurrent dvt and pe after initial therapy, supporting long-term vascular health and reducing the likelihood of future clotting events.
• Provides prophylaxis against postoperative dvt and pe in patients undergoing hip or knee replacement surgery, lowering the risk of serious thromboembolic complications.

Warnings & Contraindications:

• Contraindicated in patients with active clinically significant bleeding.
• Contraindicated in patients with severe hypersensitivity (allergic) reactions to apixaban or any component of the formulation.
• Use with extreme caution in patients with increased risk of bleeding, including those with bleeding disorders, recent major surgery, recent brain or spinal injury, active peptic ulcer, severe uncontrolled hypertension, or recent hemorrhagic stroke.
• Use with caution in patients with severe liver impairment or hepatic disease associated with coagulopathy, as this may increase bleeding risk.
• Renal impairment: dose adjustment or special monitoring may be required in patients with reduced kidney function. Follow physician guidance strictly.
• Concomitant use with other anticoagulants, antiplatelet agents, nonsteroidal anti-inflammatory drugs (nsaids), selective serotonin reuptake inhibitors (ssris), or serotonin norepinephrine reuptake inhibitors (snris) may increase bleeding risk; such combinations should be carefully evaluated by a doctor.
• Spinal/epidural anesthesia or puncture: patients receiving neuraxial anesthesia or undergoing spinal puncture while on Eliquis are at risk of developing epidural or spinal hematomas, which may result in long-term or permanent paralysis. Careful monitoring and timing of doses are required.
• Inform all healthcare providers and dentists that you are taking Eliquis 5 mg before any surgery, dental procedure, or invasive intervention.
• Consult your doctor before use if pregnant, nursing, planning pregnancy, taking other medications, or if you have medical conditions such as liver disease, kidney disease, bleeding disorders, recent surgery, or uncontrolled hypertension.
• Not intended to diagnose, treat, cure, or prevent any disease outside the approved medical indications. Use only under medical supervision.
• Keep out of reach of children.
• Do not share this medication with others, even if they have similar symptoms or conditions.

Side Effects:

• Common side effects may include easy bruising, mild nosebleeds, gum bleeding, or minor bleeding from cuts that may take longer than usual to stop.
• Other possible side effects: anemia (low red blood cell count), nausea, or mild gastrointestinal discomfort.
• Serious side effects (seek immediate medical attention): prolonged or heavy bleeding, blood in urine or stools (red or black/tarry stools), coughing or vomiting blood, severe or unexplained bruising, sudden severe headache, dizziness or fainting, weakness or numbness (especially on one side of the body), difficulty speaking, vision changes, or any signs of stroke or internal bleeding.
• Allergic reactions are rare but may include rash, itching, swelling of the face, lips, tongue, or throat, and difficulty breathing. Stop the medication and seek urgent medical help if these occur.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children. Do not use after the expiry date stated on the packaging. Store at room temperature according to the manufacturer’s recommendations on the leaflet.

Specifications:

• Form: Film-coated tablets for oral use.
• Strength: 5 mg apixaban per tablet.
• Pack size: 20 film-coated tablets per pack (20 f.c. tabs.).
• Intended use: Prescription anticoagulant medicine for adults.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.